Locally Advanced Pancreatic Adenocarcinoma: Update and Progress

  • John Ng Columbia University College of Physicians and Surgeons, New York Presbyterian Hospital. New York, NY, USA
  • Chi Zhang Columbia University College of Physicians and Surgeons, New York Presbyterian Hospital. New York, NY, USA
  • Daniela Gidea-Addeo Columbia University College of Physicians and Surgeons, New York Presbyterian Hospital. New York, NY, USA
  • Muhammad Wasif Saif Columbia University College of Physicians and Surgeons, New York Presbyterian Hospital. New York, NY, USA
Keywords: Combined Modality Therapy, erlotinib, Fluorouracil, gemcitabine, Pancreatic Neoplasms, Radiation, Radiotherapy

Abstract

 

Pancreatic cancer, the 4th leading cause of cancer death in the U.S., remains a challenging disease for the oncology community. Less than 20% of all cases are potentially cured by surgical resection, while the large majority of cases are deemed either unresectable or metastatic upon diagnosis. Advances in treating locally advanced pancreatic cancer have been few and modest. In this year’s American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, three abstracts (#252, #254, #313) were presented with novel approaches towards treating locally advanced pancreatic cancer. Surgery for recurrent disease, a promising new chemoradiation regimen, and the application of an exciting multi-agent regimen (FOLFIRINOX: oxaliplatin, irinotecan, leucovorin, 5-fluorouracil) in a non-clinical trial setting, highlight the novel approaches focused on the management of this difficult disease.

 

Downloads

Download data is not yet available.

Author Biographies

John Ng, Columbia University College of Physicians and Surgeons, New York Presbyterian Hospital. New York, NY, USA

Chief Resident, Columbia University Medical Center.

Chi Zhang, Columbia University College of Physicians and Surgeons, New York Presbyterian Hospital. New York, NY, USA

Resident, Columbia University Medical Center.

Daniela Gidea-Addeo, Columbia University College of Physicians and Surgeons, New York Presbyterian Hospital. New York, NY, USA

Professor, Columbia University Medical Center.

Muhammad Wasif Saif, Columbia University College of Physicians and Surgeons, New York Presbyterian Hospital. New York, NY, USA

Professor, Columbia University Medical Center.

References

Siegel R,Naishadham D,Jemal A. Cancer Statistics, 2012. CA Cancer J Clin. 2012;62(1):10-29.

Johung K, Saif MW, Chang BW. Treatment of locally advanced pancreatic cancer: the role of radiation therapy. Int J RadiatOncolBiol Phys. 2012; 82(2):508-18.

National Comprehensive Cancer Network. Practice guidelines in oncology: Pancreatic adenocarcinoma. 2011. Available at:www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf.

Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst. 1988 Jul 20;80(10):751-5.

Klaassen DJ, MacIntyre JM, Catton GE, et al. Treatment of locally unresectable cancer of the stomach and pancreas: A randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil - an Eastern Cooperative Oncology Group study. J ClinOncol. 1985;3:373-378.

Chauffert B, Mornex F, Bonnetain F, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive resultsof the 2000-01 FFCD/SFRO study. Ann Oncol. 2008;19:1592-1599.

Loehrer PJ Sr, Feng Y, Cardenes H, et al. Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial. J ClinOncol.2011;29:4105-4112.

Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817-25.

Thomas RM, Truty MJ, Fleming JB, Pisters PWT, Lee JE, Rice DC, et al. Selective reoperation for locally recurrent or metastatic pancreatic ductal adenocarcinoma following primary pancreatic resection. J Clin Oncol 30, 2012 (suppl 4; abstr 252)

Skinner HD, Javle MM, Wolff RA, Clemons MV, Munsell MF, Delclos ME, et al. Phase I trial of radiotherapy with concurrent bevacizumab, erlotinib, and capecitabine for locally advanced pancreatic cancer (LAPC). J Clin Oncol 30, 2012 (suppl 4; abstr 254)

Faris JE, Hong TS, McDermott S, Guimaraes AR, Sahani D, Clark JW, et al. FOLFIRINOX in locally advanced or metastatic pancreatic cancer. J Clin Oncol 30, 2012 (suppl 4; abstr 313)

Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25:1960-6.

Scheele J, Altendorf-Hofmann A. Resection of colorectal liver metastases. Langenbecks Arch Surg. 1999;384(4):313-27.

No image available
Published
2012-03-10
How to Cite
NgJ., ZhangC., Gidea-AddeoD., & SaifM. (2012). Locally Advanced Pancreatic Adenocarcinoma: Update and Progress. JOP. Journal of the Pancreas, 13(2), 155-158. https://doi.org/10.6092/1590-8577/710
Section
Highlights from the “2012 ASCO Gastrointestinal Cancers Symposium”. San Francisco, CA, USA. January 19-21, 2012